Dr. Julian Zachmann

Investment Manager

Dr. Julian Zachmann

Investment Manager

As a senior scientist in computational drug discovery, Julian Zachmann has successfully guided an anti-cancer drug through preclinical studies within 2 years. He then founded his own start-up in the field of Artificial Intelligence / Digital Health and subsequently completed an MBA at INSEAD. Since 2019 Julian has been working in the Life Science Team at HTGF and is very interested in artificial intelligence applications.

Contact

Telefon:
+49 – (0) 228 – 82300 – 166

Posts & mentions

Press
15. September 2022

Aignostics Raises €14m Series A to Advance AI-powered Pathology

Oversubscribed financing round with top-tier life science investors, led by Wellington PartnersSpin-off from Charité – Universitätsmedizin Berlin developing sophisticated AI models to improve understanding, diagnosis and treatment of complex diseasesFunds to expand US market presence and further advance AI platform Berlin, Germany, 15th September 2022 – Aignostics, a spin-off from Charité – Universitätsmedizin Berlin, developing novel digital pathology solutions with “
 
Press
7. June 2022

Invasight closes CHF 4.5 million oversubscribed seed round

The funds will accelerate the development of targeted therapies with superior safety profile for patients with invasive cancers. Zurich, Switzerland, 7 June 2022 – Invasight AG, a Swiss pre-clinical stage biotech company with a mission to develop their breakthrough targeted therapies for invasive cancers, announced the closing of a CHF 4.5 million seed round. The seed financing round was led by OCCIDENT and co-led by JFG Life Sciences Foundation, with participation from Verve Ventures,
 
Press
Cutanos Gründerteam
5. July 2021

Cutanos closes first financing round with investor consortium from Austria and Germany

Max Planck spin-off develops immunotherapies through innovative platform technology Vienna, July 5 2021 - Cutanos GmbH, a Viennese biotech start-up, announces the successful closing of its first financing round with KHAN Technology Transfer Fund I (KHAN-I), High-Tech Gründerfonds (HTGF), IST cube and another private investor. Cutanos was founded in early 2021 as a spin-off of the Max Planck Institute of Colloids and Interfaces. The core of the company is its Langerhans Cell Target Del